96-Week FOREST-HCM Data Support Aficamten Use in Nonobstructive HCM

New 96-week data from the FOREST-HCM trial is shedding further light on the potential of aficamten among patients with nonobstructive hypertrophic cardiomyopathy (nHCM).

Presented at the Heart Failure Society of America (HFSA) Annual Scientific…